ADC Therapeutics appoints David Gilman as Chief Business & Strategy Officer | News

ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of industry veteran David Gilman as its new Director of Business and Strategy, reporting to CEO Ameet Mallik, effective July 1. In this role, David Gilman is a member of the company’s senior management and is responsible for all business development strategies and portfolio globally.

This press release contains multimedia content. View the full announcement here:

David Gilman, dyrektor ds. biznesu i strategii, <a href=ADC Therapeutics (photo: Business Wire) “/>

David Gilman, director of business and strategy, ADC Therapeutics (photo: Business Wire)

“David Gilman is an experienced director of business development and strategy with an outstanding performance in the life sciences industry,” said Ameet Mallik, president and CEO of ADC Therapeutics. “We are delighted to have David join our leadership team at this pivotal moment in the development of ADC Therapeutics.”

Gilman is a director with over 25 years of experience in the pharmaceutical industry. In 2018-2019 he worked for Novartis as Global Head of Portfolio Strategy and Business Development in the Novartis Oncology business unit. Prior to joining ADC Therapeutics, he worked at ClearView Healthcare Partners, a global strategy and life science consulting company, where in 2019-2022 he played a key role in direct customer engagement as well as global expansion and customer service in key business development initiatives, including in. as well as in strategic transactions. Prior to ClearView and Novartis, Gilman spent 17 years at The Frankel Group / Huron Consulting Group where he focused on facilitating numerous and meaningful pharmaceutical partnerships for his clients.

Gilman holds an MBA from the University of Texas at Austin and a BA from the University of Chicago.

About ADC therapy

ADC Therapeutics (NYSE: ADCT) is a commercial biotechnology company that improves the quality of life of cancer patients with the next generation of targeted antibody drug conjugates (ADCs). The company continues to develop its own PBD-based ADC technology to change the paradigm of treating patients with haematological and solid tumors.

ADC Therapeutics targeting CD19 AWK ZYNLONTA (Loncastuximab-Tesirin-Lpyl) is FDA approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also being developed as a combination therapy with other agents. Cami (camidanlumab thesirine) is being investigated in a pivotal Phase 2 clinical trial in relapsed or refractory Hodgkin’s lymphoma and in a Phase 1b clinical study in various advanced solid tumors. In addition to ZYNLONT and Cami, ADC Therapeutics has several ADCs undergoing clinical and preclinical development.

ADC Therapeutics is based in Lausanne (Biople), Switzerland, with offices in London, San Francisco Bay Area and New Jersey. Visit for more information. You can also follow the company on Twitter and LinkedIn.

ZYNLONTA is a registered trademark of ADC Therapeutics SA.

The official and authorized version is the source language in which the original text is published. Translations are included for better understanding. Only the originally published language version is valid. Therefore, compare the translations with the original language version of the publication.

Selected leveraged products in the ADC Therapeutics AG priv nom -C- actWith knockouts, speculative investors can disproportionately participate in price movements. Just choose the lever you want and we’ll show you the right products open to ADC Therapeutics AG Act priv nom -C-

The leverage must be between 2 and 20

No data

Leave a Comment